Literature DB >> 19996881

Cognitive and academic outcome after benign or malignant cerebellar tumor in children.

Delphine Callu1, Delphine Viguier, Françoise Laroussinie, Stéphanie Puget, Nathalie Boddaert, Virginie Kieffer, Hélène Piana, Sylvie Escolano, Dominique Renier, Christian Sainte-Rose, Jacques Grill, Georges Dellatolas.   

Abstract

OBJECTIVE: To examine the impact of malignancy and location of the cerebellar tumor on motor, cognitive, and psychologic outcome.
BACKGROUND: Although many studies focus on long-term outcome after cerebellar tumor treatment in childhood, the impact of its precise location remains unclear. PATIENTS AND METHODS: Children, aged from 6 to 13 years, with a cerebellar malignant tumor (MT; MT group, n=20) or a cerebellar benign tumor (BT; BT group, n=19) were examined at least 6 months after the end of treatment using the international cooperative ataxia rating scale, the Purdue pegboard for manual skill assessment and the age-adapted Weschler scale. Structural changes in brain anatomy were evaluated and parents and teachers answered 2 independent questionnaires.
RESULTS: Parents and teachers reported high rate of learning and academic difficulties, but without any difference with respect to the type of tumor. However, children with cerebellar MT showed increased cognitive and motor difficulties compared with children with cerebellar BT. Cerebellar signs at clinical examination and manual skill impairment were strongly associated with cognitive difficulties. Both motor and cognitive impairments were found to be associated with extension of the lesion to the dentate nuclei.
CONCLUSIONS: Dentate nuclei lesions are major risk factors of motor and cognitive impairments in both cerebellar BT and MT.

Entities:  

Mesh:

Year:  2009        PMID: 19996881     DOI: 10.1097/WNN.0b013e3181bf2d4c

Source DB:  PubMed          Journal:  Cogn Behav Neurol        ISSN: 1543-3633            Impact factor:   1.600


  6 in total

1.  Cerebellar mutism: definitions, classification and grading of symptoms.

Authors:  Thora Gudrunardottir; Astrid Sehested; Marianne Juhler; Jacques Grill; Kjeld Schmiegelow
Journal:  Childs Nerv Syst       Date:  2011-07-06       Impact factor: 1.475

Review 2.  Consensus paper on post-operative pediatric cerebellar mutism syndrome: the Iceland Delphi results.

Authors:  Thora Gudrunardottir; Angela T Morgan; Andrew L Lux; David A Walker; Karin S Walsh; Elizabeth M Wells; Jeffrey H Wisoff; Marianne Juhler; Jeremy D Schmahmann; Robert F Keating; Coriene Catsman-Berrevoets
Journal:  Childs Nerv Syst       Date:  2016-05-03       Impact factor: 1.475

3.  Morphological brain lesions of pediatric cerebellar tumor survivors correlate with inferior neurocognitive function but do not affect health-related quality of life.

Authors:  Rajiv Kumar Khajuria; Friederike Blankenburg; Ines Wuithschick; Stefan Rueckriegel; Ulrich-Wilhelm Thomale; Michael Mansour; Pablo Hernáiz Driever
Journal:  Childs Nerv Syst       Date:  2015-02-17       Impact factor: 1.475

Review 4.  Childhood Brain Tumors: a Systematic Review of the Structural Neuroimaging Literature.

Authors:  Alyssa S Ailion; Kyle Hortman; Tricia Z King
Journal:  Neuropsychol Rev       Date:  2017-06-23       Impact factor: 7.444

5.  A prospective behavioral and imaging study exploring the impact on long-term memory of radiotherapy delivered for a brain tumor in childhood and adolescence.

Authors:  Eloïse Baudou; Jérémie Pariente; Patrice Péran; Fatima Tensaouti; Lisa Pollidoro; Déborah Meligne; Anne Ducassou; Hélène Gros-Dagnac; Germain Arribarat; Jean-Pierre Desirat; Anne-Isabelle Bertozzi; Marion Gambart; Delphine Larrieu-Ciron; Dominique Barbolosi; Xavier Muracciole; Béatrice Lemesle; Annick Sevely; Margaux Roques; Mathilde Cazaux; Jessica Tallet; Jeremy Danna; Yves Chaix; Anne Laprie
Journal:  Clin Transl Radiat Oncol       Date:  2021-11-07

Review 6.  Core deficits and quality of survival after childhood medulloblastoma: a review.

Authors:  Mathilde Chevignard; Hugo Câmara-Costa; François Doz; Georges Dellatolas
Journal:  Neurooncol Pract       Date:  2016-08-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.